Association between CKD-MBD and mortality in older patients with advanced CKD—results from the EQUAL study
Lorenza Magagnoli(AOL (United States)), Nicholas C Chesnaye(Amsterdam Neuroscience), Claudia Torino(Istituto di Fisiologia Clinica), Christoph Wanner(Universitätsklinikum Würzburg), Magdalena Krajewska(Wrocław University of Science and Technology), Peter Stenvinkel(Karolinska Institutet), Marie Evans(Karolinska University Hospital), Kitty J. Jager(Amsterdam University Medical Centers), Christiane Drechsler(Universitätsklinikum Würzburg), Gaetana Porto(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Esther de Rooij(Leiden University Medical Center), Maciej Szymczak(Wroclaw Medical University), Friedo W. Dekker(Leiden University Medical Center), Fergus Caskey, Mario Cozzolino(AOL (United States)), Maria Pippias(North Bristol NHS Trust)
Cited by 37
Related Papers
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|969
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
|The Lancet|2017|923
A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases
|Kidney International|2019|886